Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...
While Rejoyn is approved for depression, "it is not designed as a standalone treatment," says King; the approval is as a supplement to existing treatments or therapy to improve their effectiveness.
"Today it was a bit of luck but it’s still worth a goal. I’m very happy," a laughing Pulisic said in Italian. "I didn’t try to do that but it was a good cross, I’ll say that, and after a ...